Re: Contingent Agreement on Final Payment and Termination of the Striant® Investment and Royalty AgreementContingent Agreement on Final Payment and Termination of the Striant® Investment and Royalty Agreement • March 4th, 2010 • Columbia Laboratories Inc • Pharmaceutical preparations • Delaware
We refer to the Investment and Royalty Agreement between Columbia Laboratories, Inc. (“Columbia”) and PharmaBio Development Inc. (“PharmaBio”), dated March 5, 2003, as amended by a letter agreement dated January 26, 2004, supplemented by a letter agreement dated April 14, 2006 and amended by a second amendment dated July 22, 2009 (the “Agreement”; capitalized terms that are not defined in this letter agreement shall have the meanings as set forth in the Agreement). The purpose of this letter agreement is to provide for the early termination of the Agreement by setting forth the terms and conditions under which Columbia will pay the Minimum Royalty Amount due at the end of the seventh (7th) Annual Period under Section 2.3 of the Agreement on a date earlier than otherwise required under such section.
